Johnson & Johnson beats estimates, raises 2026 guidance

Investing.com -- Johnson & Johnson (NYSE: JNJ) reported its latest quarterly results ahead of the open on Tuesday, exceeding analyst expectations.

Adjusted earnings per share of $2.59 beat the consensus estimate of $2.53 by $0.06. Revenue reached $25.4 billion, slightly above the $25.38 billion consensus, representing a 5.9% increase from $24.0 billion in the same quarter last year.

The company raised its full-year 2026 guidance, now projecting adjusted EPS of $11.05-$11.15, compared to the analyst consensus of $11.08. Revenue guidance was increased to $101.0-$101.4 billion, with the $101.2 billion midpoint matching the consensus estimate of $101.4 billion.

Shares rose 0.1% following the announcement.

"Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio," said Joaquin Duato, Chairman and Chief Executive Officer.

The Innovative Medicine segment drove growth with sales of $16.8 billion, up 7.7% from the prior year, led by strong performance from TREMFYA, DARZALEX, CARVYKTI, and TECVAYLI. The MedTech segment posted $8.6 billion in sales, up 2.5% YoY, with growth in electrophysiology products and Shockwave in Cardiovascular.

U.S. sales increased 9.1% to $15.0 billion, while international sales grew 1.5% to $10.4 billion.

Original Article

You May Also Be Interested In

• Erste Group Downgrades Johnson & Johnson (JNJ) to Hold
• BofA flags five chemical stocks amid tough Q3 earnings outlook
• Seagate stock rises on analyst price target upgrades